Home > Gastroenterology > ECCO 2022 > Miscellaneous Topics > Comparable safety profiles of biological therapies in elderly patients with IBD

Comparable safety profiles of biological therapies in elderly patients with IBD

Presented By
Dr Gustavo Drügg Hahn, McGill University Health Center, Canada

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ECCO 2022
A systematic review comparing the safety profiles of biological therapies in elderly patients with inflammatory bowel disease (IBD) did not reveal significant differences in the rate of adverse events (AEs) between the different treatments. However, infusion/injection reactions occurred more often in patients treated with anti-TNFs. The authors concluded that larger studies are needed to establish sequencing recommendations of biological therapies in this population. Dr Gustavo Drügg Hahn (McGill University Health Center, Canada) and colleagues conducted a systematic review and meta-analysis to study the safety profiles of biological therapies in elderly patients with IBD [1]. In total, 17 studies assessing the safety profiles of anti-TNFs, vedolizumab, and ustekinumab in participants with IBD aged 60 years or older were included in the systematic review. No significant difference was detected in the rate of AEs for participants treated with anti-TN...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on